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MTB = transgenic mouse line with MMTV-LTR-driven expression of reverse tetracycline-dependent transactivator ‘Tet-On’ in the mammary
epithelium; TAN = transgenic mouse line with doxycycline-inducible expression of NeuNT (TetO-NeuNT); TWNT = transgenic mouse line with
doxycycline-inducible expression of Wnt1 (TetO-Wnt1).
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Introduction
Cancer is a multistage process. Cells are selected after
accumulating successive genetic lesions in oncogenes
and tumor suppressor genes, resulting in independence
from the normal restraints that regulate growth, prolifera-
tion, survival, differentiation and migration [1–5]. Condi-
tional transgenic mouse models expressing oncogenes
involved in human cancer pathways have revolutionized
the way in which we define the contributions that these
oncogenes lend to the process of tumorigenesis. Adapta-
tion of the tetracycline-responsive gene expression system
to transgenic mice [6–9] prepared the way for develop-
ment of conditional models in which precise timing of
oncogene exposure in specific tissues initiated events that
model those that occur during the stepwise progression of
human oncogenesis [10–18].
A first application of these models was to study the poten-
tial for reversal of a dysplastic or malignant phenotype
when expression of an initiating oncogene was downregu-
lated. Determining the effect of loss of expression of the
initiating oncogene establishes the requirement of the initi-
ating oncogene for maintenance of preneoplasia and/or
neoplasia. Experiments to date reveal provocative differ-
ences in preneoplastic or neoplastic reversal between dif-
ferent initiating oncogenes and target tissues. Reversibility
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Abstract
Diversity in the pathophysiology of breast cancer frustrates therapeutic progress. We need to
understand how mechanisms activated by specific combinations of oncogenes, tumor suppressors,
and hormonal signaling pathways govern response to therapy and prognosis. A recent series of
investigations conducted by Chodosh and colleagues offers new insights into the similarities and
differences between specific oncogenic pathways. Expression of three oncogenes relevant to
pathways activated in human breast cancers (c-myc, activated neu and Wnt1) were targeted to murine
mammary epithelial cells using the same transgenic tetracycline-responsive conditional gene
expression system. While the individual transgenic lines demonstrate similarly high rates of tumor
penetrance, rates of oncogene-independent tumor maintenance and recurrence following initial
regression are significantly different, and are modifiable by mutations in specific cooperating
oncogenes or loss of tumor suppressor gene expression. The experiments make three notable
contributions. First, they illustrate that rates of tumor regression and recurrence following initial
regression are dependent upon the pathways activated by the initiating oncogene. The experiments
also demonstrate that altered expression or mutation of specific cooperating oncogenes or tumor
suppressor genes results in different rates of tumor regression and recurrence. Finally, they exemplify
the power of conditional mouse models for elucidating how specific molecular mechanisms give rise to
the complexity of human cancer.
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of salivary oncogenesis initiated by expression of the
complex oncoprotein Large Simian Virus 40 T antigen,
which disrupts both pRB-related and p53 tumor suppres-
sor pathways, is interrupted at a preneoplastic stage in a
time-dependent manner [11]. In contrast, melanomas initi-
ated by H-Ras [12], lung carcinomas initiated by K-Ras
[13], and leukemia initiated by BCR-ABL [14] remain
reversible through the neoplastic stage after expression of
the initiating oncogene is downregulated. Reversibility in
different tissues following downregulation of the single
initiating oncogene c-myc can be compared in mammary
adenocarcinomas [15] and in lymphomas [16]. Whereas
90% of the lymphomas regress after c-myc abrogation,
regression of mammary adenocarcinomas is limited by ras
mutation. Seventy-eight percent of mammary adenocarci-
nomas without ras mutation regress, while adenocarcino-
mas with ras mutation do not regress after c-myc
downregulation.
In these experiments neoplastic reversal is due either to
rapid apoptosis of tumor cells [12–14,16] or to redifferen-
tiation of cells causing arrest of proliferation and loss of
malignant potential [16]. These models are important
since they suggest that ablation of signaling from one
oncogenic pathway may be sufficient to reverse a malig-
nant phenotype. In some models it is possible that tumor
cells expressing an oncogene may have undergone adap-
tive transcriptional changes that lead to their dependence
on continued expression of the oncogene for growth and
survival. These adaptive changes might not allow the
tumor cells to switch to other proliferative pathways swiftly
enough to prevent activation of apoptotic machinery [13].
Oncogene-independent recurrent growth of tumors in
animals with regressed primary tumors was reported in a
small percentage of cases in the H-Ras-induced
melanoma [12], in c-myc-induced lymphomas [16] and in
c-myc-induced mammary adenocarcinomas [15]. Addi-
tionally, in a line of mice with longer leukemia latency, all
mice in remission due to downregulation of the BCR-ABL
transgene developed a BCR-ABL-independent, rapidly
progressing, B-cell leukemia [14]. It was hypothesized that
the prolonged exposure of the cells to BCR-ABL allowed
for the development of secondary mutations that bypass
reliance on the initial transforming event. In the c-myc
mammary adenocarcinoma model, the ras mutation was
identified as a genetic event that promotes c-myc-
independent tumor growth [15].
Reversibility and recurrence of mammary
adenocarcinomas and metastases induced by
activated Neu
Chodosh and colleagues have extended and amplified
these studies by examining the reversibility and oncogene-
independent recurrence of different initiating oncogenes in
the same target tissue, the mammary gland (Fig.1).
Transgenic mice with conditional expression of activated
Neu in mammary epithelial cells were designed (MTB/TAN
mice) to examine the dependence of continued oncogene
expression on activated Neu-initiated tumors and metas-
tases [19]. Expression of activated Neu causes hyperplas-
tic abnormalities in the mammary ductal tree, in the ductal
hyperplasia, and in the invasive mammary nodular carcino-
mas in 100% of the mice. Downregulation of activated Neu
in double transgenic MTB/TAN female mice with mammary
carcinomas showed that 94% of tumors are reversible and
regress to a nonpalpable state. Even metastatic lesions are
dependent on activated Neu for growth and also regress
following abrogation of transgene expression. However, as
frequently occurs in human cancers following initial thera-
peutic success, a significant percentage (63%) of the
regressed cancers eventually recur.
An intriguing feature of the experiments was the fact that
the percentages of primary tumors and metastases
demonstrating oncogene-independent maintenance was
increased when they were first transplanted into syn-
geneic hosts before abrogation of transgene expression.
Stromal cells surrounding tumors can secrete growth and
survival factors (such as matrix metalloproteinases), which
may promote cancer development, cancer progression,
and cancer metastasis by altering the tumor environment
Figure 1
Comparison of the rates of penetrance, of maintenance after oncogene
downregulation, and of recurrence after oncogene downregulation in
three conditional transgenic mouse models of mammary
carcinogenesis. In the Wnt1 group, the first bars depict the rates for
p53 wildtype (p53+/+) mice and the final two bars for p53
heterozygote (p53+/–) mice. The rate of oncogene-independent
explant maintenance for primary tumor and metastasis in Wnt1
transgenic mice was 0%. 1o, primary tumor; Met, metastasis. Adapted
from [15,19,21].
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[20]. For example, matrix metalloproteinases may act in
transformation by inducing apoptosis in anchorage-depen-
dent cells and/or by modifying cell cycle checkpoints
through alterations in cell adhesion. The increase in
primary tumors and metastases that resulted after trans-
plantation illustrates that tumor regression did not neces-
sarily occur after loss of oncogene expression. The
increase raises the possibility that this model can be uti-
lized to explore how the tumor environment can modify
cancer cell behavior and how stromal changes are linked
to primary epithelial cell oncogenic events.
Loss of one p53 allele alters reversal and
recurrence of Wnt-induced mammary
adenocarcinomas
Chodosh and colleagues used the same conditional
system to examine the requirement of continued Wnt1
expression in the maintenance and recurrence of
mammary cancers by developing double transgenic mice
with conditional expression of Wnt1 (MTB/TWNT mice)
[21]. In MTB/TWNT double transgenic females, induction
of Wnt1 expression by doxycycline administration results
in increased ductal side branching and in precocious lobu-
loalveolar development. Upon chronic Wnt1  exposure,
ductal hyperplasia develops into invasive mammary adeno-
carcinomas that metastasize to the lung. Similar to acti-
vated Neu, abrogation of Wnt signaling by doxycycline
withdrawal leads to rapid regression of mammary adeno-
carcinomas and lung metastases in 94% of the mice. But
intriguingly, rates of tumor reoccurrence and the require-
ment for continued oncogene expression for tumor mainte-
nance following transplantation were significantly different
from those in the activated Neu model (Fig.1). Tumors
recur in only 29% of the regressed Wnt1 tumors, and all
of the transplanted tumors and metastases regressed
after loss of oncogene expression.
As the next step, Chodosh and colleagues examined the
role of the specific tumor suppressor gene p53 in onco-
gene-independent tumor maintenance and recurrence.
Even though p53 is not required for regression of Wnt1-
induced tumors, 40% of the tumors that develop in p53
heterozygous mice do not regress when Wnt1 is down-
regulated, and a high percentage (76%) of the adenocar-
cinomas that do regress subsequently recur.
Conclusion
Conditional transgenic mouse models allow investigators
to model possible therapeutic consequences of oncogene
downregulation on the maintenance of malignancy and
recurrence. Oncogenic pathways can be examined in indi-
vidual tissues and cancer systems to determine whether
there will be oncogene-independent growth, and if so to
which alternative pathways the cells turn in order to
bypass oncogene dependence. Results from these experi-
ments may suggest alternative or adjuvant therapies.
Experiments by Chodosh and colleagues illustrate the
power of conditional transgenic mouse systems to investi-
gate the impact of different initiating oncogenes on
mammary oncogenesis, on oncogene-independent tumor
maintenance, and on recurrence following initial regres-
sion. The results exemplify the differences between onco-
genes. While 56% of c-myc-induced mammary cancers
demonstrate oncogene-independent tumor maintenance,
only 6% of activated Neu-induced and Wnt1-induced
mammary cancers demonstrate oncogene-independent
tumor maintenance. While only a fraction of the c-myc-
induced mammary cancers that regress after downregula-
tion of oncogene expression subsequently recur, 63% of
regressed activated Neu mammary cancers and 29% of
regressed Wnt1 mammary cancers recur. The Chodosh
laboratory also shows us examples of how mutations in
cooperating oncogenes, changes in tumor environment,
and loss of tumor suppressor gene expression can alter
oncogene-independent tumor maintenance and recur-
rence. Oncogene-independent maintenance of c-myc-
induced mammary adenocarcinomas is facilitated by ras
mutation, the oncogene-independent maintenance of acti-
vated Neu-induced adenocarcinomas and metastases is
altered when they are transplanted to a different environ-
ment, and p53 heterozygosity promotes oncogene-inde-
pendent maintenance and recurrence of Wnt1-induced
adenocarcinomas.
Further exploitation of conditional systems will provide even
more detailed information on the diverse molecular mecha-
nisms that act together to produce human cancer. It may be
possible to explore earlier stages in the development of
cancers using these conditional systems to determine
whether premalignant lesions are present, and if so how they
regress after oncogene downregulation. In addition to onco-
gene dependence, the development of the MTB mice, which
allow direct targeting of the mouse mammary epithelial cells,
allows for the study of other factors that contribute to
mammary adenocarcinoma progression. For example, repro-
ductive history is an important risk factor for human breast
cancer. It has also been shown in mice that the number of
pregnancies hastens the development of mammary adeno-
carcinoma in HER-2/neu mice [22]. The effect of multiple
pregnancies and ovariectomy on tumor latency and cancer
regression can also be examined in these models. Use of
this knowledge should help us to understand the limitations
of current therapies that target specific pathways and to
promote development of new ones.
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